OOS, OOT, OOC, and OOSC - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Current GMPs demand full understandng of out-of-control concepts. This article contains bonus material.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 46-47

Lynn D. Torbeck
The pharmaceutical industry is not immune to rampant proliferation of acronyms. To alleviate confusion about being out-of-control (OOC), this column proposes concepts and definitions for the industry.

No plant manager wants to hear the words, "Your process is out-of-control." The process was probably designed, developed, nursed, nurtured, fine-tuned, tested, and coddled until it met the definition of a validated process (1). Now, someone who was never involved in process development declares it is as OOC. Not a welcome message and it begs the question, "out-of-control for what?" Modifiers and definitions are needed.

There are several ways that the process can be described as OOC. There could be equipment failures or changes in the raw materials used. The process could be financially OOC (i.e., losing money), or out-of-regulatory-control with cGMP violations. Perhaps the operators are creating excessive deviations and confusion by not following the standard operating procedures because of a dysfunctional work culture; managerial malfeasance has resulted in the demise of several companies in the past. If we say it is OOC, we are obligated to specify how.

The most notorious lack of control is being out-of-specification (OOS, 2). An OOS situation exists when a reportable result collected at a single point in time exceeds a predetermined specification (3).

This event precipitates a cascade of activity as described in the OOS guidance. This has been discussed extensively for years and is well understood by the industry.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here